Stephanie van Hoppe

89 ABCB1 restricts brain penetration of the BTK inhibitor ibrutinib while CYP3A limits its oral bioavailability 23. Schinkel, A.H., et al., Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug- transporting) P-glycoproteins. Proc Natl Acad Sci U S A, 1997. 94(8): p. 4028-33. 24. Jonker, J.W., et al., The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15649-54. 25. Jonker, J.W., et al., The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med, 2005. 11(2): p. 127-9. 26. vanWaterschoot, R.A., et al., Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res, 2009. 69(23): p. 8996-9002. 27. Dai, H., et al., Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther, 2003. 304(3): p. 1085-92. 28. Goh, L.B., et al., Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol, 2002. 64(11): p. 1569-78. 29. European Medicines Agency. available from: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/003791/WC500177775.pdf, 2014. 30. Bernard, S., et al., Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood, 2015. 126(14): p. 1695-8. 31. Boudin, L., et al., Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome. Leuk Lymphoma, 2018: p. 1-3. 32. Lionakis, M.S., et al., Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell, 2017. 31(6): p. 833-843 e5. 33. Mason, C., et al., Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol, 2017. 179(2): p. 339-341. 34. Hiemcke-Jiwa, L.S., et al., Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement. Leuk Lymphoma, 2018. 59(5): p. 1256-1259. 35. Uchida, Y., et al., Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem, 2011. 117(2): p. 333-45. 36. Drean, A., et al., ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. J Neurooncol, 2018. 138(3): p. 479-486. 37. Olarte Carrillo, I., et al., Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia. Hematology, 2017. 22(5): p. 286-291. 38. Kort, A., et al., Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res, 2015. 32(7): p. 2205-16. 39. Kort, A., et al., Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). Mol Pharm, 2017. 14(10): p. 3258-3268. 40. van Herwaarden, A.E., et al., Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest, 2007. 117(11): p. 3583-92.